Cocrystal pharma selects two lead antiviral drug candidates for its covid-19 oral drug program

Novel broad-spectrum oral lead candidates cdi-988 and cdi- 873 , discovered using cocrystal's antiviral drug discovery platform , demonstrate superior in vitro potency against sars-cov-2 and activity against all variants of concern including omicron
COCP Ratings Summary
COCP Quant Ranking